ES2108455T3 - Ensayo en celulas para diagnosticar la enfermedad de alzheimer. - Google Patents

Ensayo en celulas para diagnosticar la enfermedad de alzheimer.

Info

Publication number
ES2108455T3
ES2108455T3 ES94915953T ES94915953T ES2108455T3 ES 2108455 T3 ES2108455 T3 ES 2108455T3 ES 94915953 T ES94915953 T ES 94915953T ES 94915953 T ES94915953 T ES 94915953T ES 2108455 T3 ES2108455 T3 ES 2108455T3
Authority
ES
Spain
Prior art keywords
disease
alzheimer
cell test
diagnose alzheimer
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94915953T
Other languages
English (en)
Inventor
Daniel L Alkon
Rene Etcheberrigaray
Ito Etsuro
Gary E Gibson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cornell Research Foundation Inc
US Department of Health and Human Services
Original Assignee
Cornell Research Foundation Inc
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cornell Research Foundation Inc, US Department of Health and Human Services filed Critical Cornell Research Foundation Inc
Application granted granted Critical
Publication of ES2108455T3 publication Critical patent/ES2108455T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA PRESENTE INVENCION ES UN METODO PARA EL DIAGNOSTICO DE LA ENFERMEDAD DE ALZHEIMER UTILIZANDO CELULAS HUMANAS ESPECIFICAMENTE, EL METODO DETECTA DIFERENCIAS ENTRE LOS CANALES DE POTASIO EN CELULAS DE UN PACIENTE CON ALZHEIMER Y DONANTES NORMALES, Y LAS DIFERENCIAS EN CONCENTRACIONES DE CALCIO INTRACELULARES ENTRE CELULAS NORMALES Y CELULAS DE ALZHEIMER EN RESPUESTA A SUSTANCIAS QUIMICAS CONOCIDAS POR INCREMENTAR LOS NIVELES DE CALCIO INTRACELULAR.
ES94915953T 1993-05-03 1994-05-02 Ensayo en celulas para diagnosticar la enfermedad de alzheimer. Expired - Lifetime ES2108455T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/056,456 US5580748A (en) 1993-05-03 1993-05-03 Diagnostic tests for alzheimers disease

Publications (1)

Publication Number Publication Date
ES2108455T3 true ES2108455T3 (es) 1997-12-16

Family

ID=22004526

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94915953T Expired - Lifetime ES2108455T3 (es) 1993-05-03 1994-05-02 Ensayo en celulas para diagnosticar la enfermedad de alzheimer.

Country Status (12)

Country Link
US (1) US5580748A (es)
EP (1) EP0697111B1 (es)
JP (1) JPH09500202A (es)
AT (1) ATE155888T1 (es)
AU (1) AU689776B2 (es)
CA (1) CA2162048A1 (es)
DE (1) DE69404460T2 (es)
DK (1) DK0697111T3 (es)
ES (1) ES2108455T3 (es)
GR (1) GR3025126T3 (es)
HK (1) HK1001500A1 (es)
WO (1) WO1994025872A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6107050A (en) * 1993-05-03 2000-08-22 The United States Of America As Represented By The Department Of Health And Human Services Diagnostic test for alzheimers disease
US5976816A (en) * 1993-05-03 1999-11-02 The United States Of America As Represented By The Department Of Health And Human Services Cell tests for alzheimer's disease
US6300085B1 (en) 1993-05-03 2001-10-09 The United States Of America As Represented By The Department Of Health And Human Services Diagnostic method for Alzheimer's disease
US6573063B2 (en) * 1995-10-04 2003-06-03 Cytoscan Sciences, Llc Methods and systems for assessing biological materials using optical and spectroscopic detection techniques
US5902732A (en) * 1995-10-04 1999-05-11 Cytoscan Sciences Llc Drug screening process measuring changes in cell volume
US6183975B1 (en) * 1997-02-24 2001-02-06 J. Jay Gargus Method of detection of congenital disease
EP1031034A4 (en) * 1997-11-10 2004-11-17 Bristol Myers Squibb Co METHOD FOR DIAGNOSTICATING ALZHEIMER'S DISEASE
US6087118A (en) * 1999-03-04 2000-07-11 Bristol-Myers Squibb Company Method for diagnosing alzheimer's disease
AU5908300A (en) * 1999-07-01 2001-01-22 Eli Lilly And Company Prevention and treatment of amyloid-associated disorders
AU2001255234A1 (en) * 2000-04-05 2001-10-23 Neurologic, Inc. Cellular calcium responce for diagnosis of alzheimer's disease
US6495335B2 (en) 2000-12-07 2002-12-17 Mario Chojkier Compositions and methods for diagnosing alzheimer's disease
GB0107231D0 (en) 2001-03-22 2001-05-16 Imp College Innovations Ltd Patch clamp
US20050065205A1 (en) * 2002-03-07 2005-03-24 Daniel Alkon Methods for Alzheimer's disease treatment and cognitive enhance
US6825229B2 (en) 2002-03-07 2004-11-30 Blanchette Rockefeller Neurosciences Institute Methods for Alzheimer's Disease treatment and cognitive enhancement
US20080004332A1 (en) * 2002-03-07 2008-01-03 Alkon Daniel L Methods for alzheimer's disease treatment and cognitive enhancement
TW201207390A (en) 2004-05-18 2012-02-16 Brni Neurosciences Inst Method for screening agent for antidepressant activity
WO2007016202A1 (en) 2005-07-29 2007-02-08 Blanchette Rockefeller Neurosciences Institute Use of a pkc activator, alone or combined with a pkc inhibitor to enhance long term memory
WO2007056160A2 (en) * 2005-11-03 2007-05-18 Redpoint Bio Corporation High throughput screening assay for the trpm5 ion channel
WO2008013573A1 (en) 2006-07-28 2008-01-31 Blanchette Rockefeller Neurosciences Institute Methods of stimulating cellular growth, synaptic remodeling and consolidation of long-term memory
EP2754448A3 (en) * 2007-02-09 2014-12-24 Blanchette Rockefeller Neurosciences, Institute Therapeutic effects of bryostatins, bryologs, and other related substances on head trauma-induced memory impairment and brain injury
CL2007002908A1 (es) * 2007-10-09 2008-05-30 Univ Concepcion Procedimiento electroquimico in vitro para evaluar capacidad neurotoxica de estructuras, principios activos y/o compuestos de interes en celulas vivas y que comprende medir y cuantificar los parametros electricos en membranas expuestas a dichos agreg
JP6058395B2 (ja) * 2009-10-02 2017-01-11 ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート アルツハイマー病の診断のための繊維芽細胞成長パターン
WO2014183023A1 (en) 2013-05-09 2014-11-13 Trustees Of Boston University Using plexin-a4 as a biomarker and therapeutic target for alzheimer's disease
JP2017505756A (ja) 2013-12-13 2017-02-23 ザ ジェネラル ホスピタル コーポレイション 可溶性高分子量（ｈｍｗ）タウ種およびその用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4925664A (en) * 1986-10-20 1990-05-15 University Of Utah Spider toxins and methods for their use as blockers of calcium channels and amino acid receptor function
WO1989009600A1 (en) * 1988-04-08 1989-10-19 Massachusetts Institute Of Technology Method and composition for treating neurological disorders

Also Published As

Publication number Publication date
US5580748A (en) 1996-12-03
AU689776B2 (en) 1998-04-09
AU6778494A (en) 1994-11-21
EP0697111A1 (en) 1996-02-21
DK0697111T3 (da) 1998-03-02
ATE155888T1 (de) 1997-08-15
DE69404460T2 (de) 1998-02-26
EP0697111B1 (en) 1997-07-23
HK1001500A1 (en) 1998-06-19
CA2162048A1 (en) 1994-11-10
GR3025126T3 (en) 1998-02-27
JPH09500202A (ja) 1997-01-07
WO1994025872A1 (en) 1994-11-10
DE69404460D1 (de) 1997-09-04

Similar Documents

Publication Publication Date Title
ES2108455T3 (es) Ensayo en celulas para diagnosticar la enfermedad de alzheimer.
DE69529992D1 (de) Cell test und diagnostischer kit für alzheimer-erkrankung
WO1999058981A3 (en) Diagnostic tests for alzheimer's disease
Schmid et al. The concept of the acid mantle of the skin: its relevance for the choice of skin cleansers
WO2000066762A3 (en) Indicators of altered mitochondrial function in predictive methods for determining risk of type 2 diabetes mellitus
ATE155811T1 (de) Menschliche cyclooxygenase-2cdna und bestimmung von menschliche cyclooxygenase-2-inhibierung
WO2001020018A3 (en) Diagnosing and treating arthritic disorders
TR199902803T2 (xx) VCAM-1' in te�hisinin daralt�lmas� i�in bile�ikler ve metodlar.
FI861972A0 (fi) Extra mild hudrengoeringskomposition.
ATE255902T1 (de) Ein anti-idiotypischer antikörper und seine verwendung in der diagnose und therapie von hiv- verwandten krankheiten
FR2623082B1 (fr) Cheville artificielle par la fixation intra-osseuse de prothese et renforts ligamentaires, ainsi que l'impacteur associe comportant des moyens de maintien de ladite cheville
ATE182180T1 (de) Lamanin-ketten: diagnostische und therapeutische verwendung
ATE250625T1 (de) IM WESENTLICHEN REINES ZONULIN ALS PHYSIOLOGISCHER MODULATOR VON ßTIGHT JUNCTIONSß BEI SÄUGERN
DE69333076D1 (de) Test und behandlung von demyelinierenden krankheiten wie multiple sklerosis
ES2148967T3 (es) Sustancias y metodos destinados al diagnostico y al tratamiento de la pre-eclampsia.
FI870818A7 (fi) Ihmisen normaaleista paksusuolen soluista saatu kudosplasminogeeni-aktivaattori.
DK1016056T3 (da) Demostrationsindretning af form som et levende væsen
BR0009771A (pt) Utilização de derivados de bisindóis indigóides capazes de penetrarem na membrana de células
ATE201680T1 (de) 2,3,4,5-tetrahydro-1h-3-benzazepin säure- additions-salze
NO986218L (no) FremgangsmÕte til Õ bestemme nµrvµr av hjerneprotein S-100
ATE178074T1 (de) Proinsulin-peptid-verbindungen für den nachweis und die behandlung von typ-i-diabetes
ATE412435T1 (de) Verwendung eines färbemittels zur anfärbung von der augenlinsenkapsel oder von an der netzhaut des auges entstandenen membranen
JPS57179109A (en) Hair treating agent
NO973666L (no) Kontrastmiddelholdige liposomer for avbildning av det intravaskulære rom
FI951778A0 (fi) Menetelmä allergian toteamiseksi

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 697111

Country of ref document: ES